A weight-loss drug, Tirzepatide, has pushed Eli Lilly's market cap to $1.21 trillion, making it the only pharmaceutical company in the U.S. stock market's 'trillion-dollar club.' Back in 2019, Eli Lilly's market cap wasn't even in the top 10 among pharma companies, sitting at just $125.8 billion. The key is that this market is just getting started—GPT says the global GLP-1 coverage for overweight individuals hasn't even reached 1%! And Eli Lilly's oral and triple-target new drugs are set to launch next year. Absolutely insane.